Subscribe To

Price Alert Latest News Economic Calendar News

NRBO / NeuroBo Pharmaceuticals Closes $14 Million Registered Direct Offering

NeuroBo Pharmaceuticals Closes $14 Million Registered Direct Offering

BOSTON, Oct. 5, 2021 /PRNewswire/ -- NeuroBo Pharmaceuticals, Inc. (Nasdaq: NRBO), a clinical-stage biotechnology company focused on developing and commercializing multimodal, disease-modifying therapies for viral, neuropathic and neurodegenerative diseases, today announced the closing of its previously announced registered direct offering of 4,307,693 shares of the Company's common stock, at a purchase price of $3.25 per share. In a concurrent private placement, the Company issued to the investors in the registered direct offering unregistered warrants to purchase up to 4,307,693 shares of the Company's common stock. Read More

Demo Live Account See Partner Details

Content Topics

Foot

Locker

Inc

Fl

Neurobo

Pharmaceuticals

Closes

Million

Registered

Direct

Offering

Stock

NRBO

Posted: Oct 5 2021, 13:13

Author Name: PRNewsWire

Views: 102120

NRBO News

NeuroBo to Present at the H.C. Wainwright 7th Annual NASH Investor Conference

By PRNewsWire
October 17, 2023

NeuroBo to Present at the H.C. Wainwright 7th Annual NASH Investor Conference

BOSTON , Oct. 17, 2023 /PRNewswire/ -- NeuroBo Pharmaceuticals, Inc. (Nasdaq: NRBO), a clinical-stage biotechnology company on a quest to transform ca

Here's Why NeuroBo Pharmaceuticals, Inc. (NRBO) Could be Great Choice for a Bottom Fisher

By Zacks Investment Research
June 6, 2023

Here's Why NeuroBo Pharmaceuticals, Inc. (NRBO) Could be Great Choice for a Bottom Fisher

NeuroBo Pharmaceuticals, Inc. (NRBO) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In

Buying Biotech Penny Stocks? 3 Things to Look For

By PennyStocks
November 10, 2022

Buying Biotech Penny Stocks? 3 Things to Look For

Are biotech penny stocks on your buy list right now The post Buying Biotech Penny Stocks? 3 Things to Look For appeared first on Penny Stocks to Buy

NeuroBo Pharmaceuticals Closes $14 Million Registered Direct Offering

By PRNewsWire
October 5, 2021

NeuroBo Pharmaceuticals Closes $14 Million Registered Direct Offering

BOSTON, Oct. 5, 2021 /PRNewswire/ -- NeuroBo Pharmaceuticals, Inc. (Nasdaq: NRBO), a clinical-stage biotechnology company focused on developing and

NeuroBo Pharmaceuticals Closes $14 Million Registered Direct Offering

By PRNewsWire
October 5, 2021

NeuroBo Pharmaceuticals Closes $14 Million Registered Direct Offering

BOSTON, Oct. 5, 2021 /PRNewswire/ -- NeuroBo Pharmaceuticals, Inc. (Nasdaq: NRBO), a clinical-stage biotechnology company focused on developing and

NeuroBo Pharmaceuticals Closes $14 Million Registered Direct Offering

By PRNewsWire
October 5, 2021

NeuroBo Pharmaceuticals Closes $14 Million Registered Direct Offering

BOSTON, Oct. 5, 2021 /PRNewswire/ -- NeuroBo Pharmaceuticals, Inc. (Nasdaq: NRBO), a clinical-stage biotechnology company focused on developing and

NeuroBo Pharmaceuticals Closes $14 Million Registered Direct Offering

By PRNewsWire
October 5, 2021

NeuroBo Pharmaceuticals Closes $14 Million Registered Direct Offering

BOSTON, Oct. 5, 2021 /PRNewswire/ -- NeuroBo Pharmaceuticals, Inc. (Nasdaq: NRBO), a clinical-stage biotechnology company focused on developing and

NeuroBo Pharmaceuticals Closes $14 Million Registered Direct Offering

By PRNewsWire
October 5, 2021

NeuroBo Pharmaceuticals Closes $14 Million Registered Direct Offering

BOSTON, Oct. 5, 2021 /PRNewswire/ -- NeuroBo Pharmaceuticals, Inc. (Nasdaq: NRBO), a clinical-stage biotechnology company focused on developing and

Risk Disclosure:

Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
We would like to remind you that the data contained in this website is not necessarily real-time nor accurate.
The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. We and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of us and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website. We may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.